260 related articles for article (PubMed ID: 7855176)
1. Persistent vacuous chewing in rats following neuroleptic treatment: relationship to dopaminergic and cholinergic function.
Glenthøj B
Psychopharmacology (Berl); 1993; 113(2):157-66. PubMed ID: 7855176
[TBL] [Abstract][Full Text] [Related]
2. Long-term treatment with low doses of the D1 antagonist NNC 756 and the D2 antagonist raclopride in monkeys previously exposed to dopamine antagonists.
Lublin H; Gerlach J; Mørkeberg F
Psychopharmacology (Berl); 1994 Apr; 114(3):495-504. PubMed ID: 7855208
[TBL] [Abstract][Full Text] [Related]
3. Chronic treatment with the D1 receptor antagonist, SCH 23390, and the D2 receptor antagonist, raclopride, in cebus monkeys withdrawn from previous haloperidol treatment. Extrapyramidal syndromes and dopaminergic supersensitivity.
Lublin H; Gerlach J; Peacock L
Psychopharmacology (Berl); 1993; 112(2-3):389-97. PubMed ID: 7871047
[TBL] [Abstract][Full Text] [Related]
4. Dopaminergic and cholinergic interaction in cataleptic responses in mice.
Ushijima I; Kawano M; Kaneyuki H; Suetsugi M; Usami K; Hirano H; Mizuki Y; Yamada M
Pharmacol Biochem Behav; 1997 Sep; 58(1):103-8. PubMed ID: 9264077
[TBL] [Abstract][Full Text] [Related]
5. D1 and D2 dopamine receptor-mediated mechanisms and behavioral supersensitivity.
Marin C; Parashos SA; Kapitzoglou-Logothetis V; Peppe A; Chase TN
Pharmacol Biochem Behav; 1993 May; 45(1):195-200. PubMed ID: 8516358
[TBL] [Abstract][Full Text] [Related]
6. Effect of D1 and D2 agonists in primates withdrawn from long-term treatment with haloperidol: the potential role of dopamine D1 receptors in dyskinesia.
Lublin H; Gerlach J; Peacock L
Clin Neuropharmacol; 1992 Dec; 15(6):448-58. PubMed ID: 1362136
[TBL] [Abstract][Full Text] [Related]
7. Chronic dopamine D1, dopamine D2 and combined dopamine D1 and D2 antagonist treatment in Cebus apella monkeys: antiamphetamine effects and extrapyramidal side effects.
Peacock L; Hansen L; Mørkeberg F; Gerlach J
Neuropsychopharmacology; 1999 Jan; 20(1):35-43. PubMed ID: 9885783
[TBL] [Abstract][Full Text] [Related]
8. Chronic neuroleptic-induced mouth movements in the rat: suppression by CCK and selective dopamine D1 and D2 receptor antagonists.
Stoessl AJ; Dourish CT; Iversen SD
Psychopharmacology (Berl); 1989; 98(3):372-9. PubMed ID: 2568657
[TBL] [Abstract][Full Text] [Related]
9. Effects of chronic discontinuous and continuous treatment of rats with a dopamine D1 receptor antagonist (NNC-756).
Glenthøj B; Bolwig TG; Hemmingsen R
Eur J Pharmacol; 1993 Oct; 242(3):283-91. PubMed ID: 8281992
[TBL] [Abstract][Full Text] [Related]
10. Differential role of dopamine D1 and D2 receptors in isoniazid-induced vacuous chewing movements.
Naidu PS; Kulkarni SK
Methods Find Exp Clin Pharmacol; 2000 Dec; 22(10):747-51. PubMed ID: 11346896
[TBL] [Abstract][Full Text] [Related]
11. Striatal synaptophysin levels are not indicative of dopaminergic supersensitivity.
Marin C; Tolosa E
Neuropharmacology; 1997 Aug; 36(8):1115-7. PubMed ID: 9294977
[TBL] [Abstract][Full Text] [Related]
12. Selective D1 and D2 receptor manipulation in Cebus monkeys: relevance for dystonia and dyskinesia in humans.
Kistrup K; Gerlach J
Pharmacol Toxicol; 1987 Sep; 61(3):157-61. PubMed ID: 2891133
[TBL] [Abstract][Full Text] [Related]
13. Effects of perospirone (SM-9018), a potential atypical neuroleptic, on dopamine D1 receptor-mediated vacuous chewing movement in rats: a role of 5-HT2 receptor blocking activity.
Ohno Y; Ishida-Tokuda K; Ishibashi T; Nakamura M
Pharmacol Biochem Behav; 1997 Aug; 57(4):889-95. PubMed ID: 9259021
[TBL] [Abstract][Full Text] [Related]
14. Studies on electroencephalogram (EEG) in rats suggest that moderate doses of cocaine or d-amphetamine activate D1 rather than D2 receptors.
Ferger B; Kropf W; Kuschinsky K
Psychopharmacology (Berl); 1994 Mar; 114(2):297-308. PubMed ID: 7838923
[TBL] [Abstract][Full Text] [Related]
15. The neurotensin antagonist SR 48692 fails to modify the behavioural responses to a dopamine D1 receptor agonist in the rat.
Stoessl AJ; James KA; Napier BJ
Neuropharmacology; 1997 Jan; 36(1):93-9. PubMed ID: 9144645
[TBL] [Abstract][Full Text] [Related]
16. The Ras homolog Rhes affects dopamine D1 and D2 receptor-mediated behavior in mice.
Quintero GC; Spano D; Lahoste GJ; Harrison LM
Neuroreport; 2008 Oct; 19(16):1563-6. PubMed ID: 18845937
[TBL] [Abstract][Full Text] [Related]
17. Dopamine receptor antagonist properties of S 14506, 8-OH-DPAT, raclopride and clozapine in rodents.
Protais P; Chagraoui A; Arbaoui J; Mocaër E
Eur J Pharmacol; 1994 Dec; 271(1):167-77. PubMed ID: 7698199
[TBL] [Abstract][Full Text] [Related]
18. Decreased striatal dopamine efflux after intrastriatal application of benzazepine-class D1 agonists is not mediated via dopamine receptors.
Zackheim JA; Abercrombie ED
Brain Res Bull; 2001 Apr; 54(6):603-7. PubMed ID: 11403986
[TBL] [Abstract][Full Text] [Related]
19. Dopamine supersensitivity and D1/D2 synergism are unrelated to changes in striatal receptor density.
LaHoste GJ; Marshall JF
Synapse; 1992 Sep; 12(1):14-26. PubMed ID: 1357762
[TBL] [Abstract][Full Text] [Related]
20. Effects of specific dopamine D1 and D2 receptor antagonists and agonists and neuroleptic drugs on emotional defecation in a rat model of akathisia.
Sachdev PS; Saharov T
Psychiatry Res; 1998 Dec; 81(3):323-32. PubMed ID: 9925183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
